HEALTH OF WOMAN. 2015.8(104):146–150 

Клинический взгляд на гиперплазию и интраэпителиальную неоплазию эндометрия молекулярно-генетические механизмы у пациенток климактерического возраста 

Веропотвелян П. Н., Веропотвелян Н. П., Бондаренко А. А., Гужевская Ю.И.

Межобластной центр медицинской генетики и пренатальной диагностики, г. Кривой Рог

Национальный медицинский университет им. А.А. Богомольца, г. Киев 

Данная статья посвящена современным аспектам гиперплазии эндометрия (ГЭ) – патогенезу, диагностике и тактике лечения. В работе охарактеризованы различные аспекты, касающиеся проблемы гиперпластических и неопластических процессов эндометрия у женщин климактерического возраста.

Представлены результаты исследований по факторам риска, диагностике ГЭ, включая применение молекулярно-генетических и иммуногистохимических методов исследования. 

Ключевые слова: иммуногистохимия, гиперплазия эндометрия, интраэпителиальная неоплазия эндометрия. 

Литература:                                                                                       
 

1. Carico E, Atlante M, Giarnieri E, Raffa S, Bucci B, Giovagnoli MR, Vecchione A. 2010. E-cadherin and alpha-catenin expression in normal, hyperplastic and neoplastic endometrium. Anticancer Res. 30(12):4993–7.

2. Shih HC, Shiozawa T, Miyamoto T, Kashima H, Feng YZ, Kurai M, Konishi I. 2004. Immunohistochemical expression of E-cadherin and beta-catenin in the normal and malignant human endometrium: an inverse correlation between E-cadherin and nuclear beta-catenin expression. Anticancer Res. 24(6):3843–50.

3. Densmore VS, Urbanski HF. 2003. Relative effect of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on gonadotropin release. J. Clin. Endocrinol. Metab. 88(5):2126–34.

4. Zaporozhan V, Tatarciuc T. 2012. Modern diagnosis and treatment of endometrial hyperplastic processes. Reproductive Endocrinology 1(3):4–12.

5. Semere LG, Ko E, Johnson NR, Vitonis AF, Phang LJ, Cramer DW, Mutter GL. 2011. Endometrial intraepithelial neoplasia: clinical correlates and outcomes. Obstet. Gynecol. 118(1):21–8.

6. Bohman YV. 2002. Guide oncogynecology. SPb .: Tome:542.

7. Park JH, Lee BI, Song ES, Whang SO, Lee WY, Cho SJ. 2008. Hypermethylation of E-cadherin in endometrial carcinoma. J. Gynecol. Oncol. 19(4):241–5.

8. Nakamura K, Hongo A, Kodama J, Hiramatsu Y. 2011. The role of hepatocyte growth factor activator inhibitor (HAI)-1 and HAI-2 in endometrial cancer. Int. J. Cancer. 128(11):2613-24. http://dx.doi.org/10.1002/ijc.25606.

9. Chernuha GE, Smetnik VP. 2001. The use of metformin in patients with ovarian hyperandrogenism and recurrent forms of endometrial hyperplasia. Problems of reproduction. 1:36–40.

10. Ohtani K, Sakamoto H, Rutherford T, Chen Z, Kikuchi A, Yamamoto T et al. 2002. Ezrin, a membrane-cytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma. Cancer Lett. 179(1):79–86.

11. Sagindykova RR, Askolskaya SI, Kogan EA, Chuprynin VD. 2014. Molecular genetic mechanisms of hyperplasia and endometrial intraepithelial neoplasia in women of perimenopausal period. Journal of Obstetrics and Gynecology 7:22–28.

12. Mutter CL. 2000. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol. Oncol. 76(3):287–90.

13. Wright TC, Holinka CF, Ferenczy A, Gatsonis CA, Mutter GL, Nicosia S, Richart RM. 2002. Estradiol-induced hyperplasia in endometrial biopsies from women on hormone replacement therapy. Аm. Surg. Pathol. 26(10):1269–75.

14. Sidorova IS, Makarov IO, Hunanian AL, Vlasov RS, Karpov DV. 2010. Pathogenesis and pathogenetically grounded therapy of chronic endometritis (clinical lecture). Оbstetrics, gynecology and reproduction 3:21–4.

15. Sun H, Enomoto T, Fujita M, Wada H, Yoshino K, Ozaki K et al. 2001. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am. J. Clin. Pathol. 115(1):32–8.

16. Asaturova AV. 2011. Modern approaches to the diagnosis of endometrial hyperplasia on the basis of molecular-biological research. Author. Dis. Cand. honey. Sciences. M:7–9.

17. Bantysh BB, Kogan EA. 2011, April 26. Epithelial-stromal relationship with the endometrial hyperplastic processes. In the book: Spider VS Kogan EA, eds. Abstracts of scientific conference. Moscow. M:9–10.

18. Granйs F, Urena JM, Rocamora N, Vilarу S. 2000. Ezrin links syndecan-2 to the cytoskeleton. J. Cell Sci. 113(7):1267–76.

19. Buda A, Pignatelli M. 2011. E-cadherin and the cytoskeletal network in colorectal cancer development and metastasis. Cell Commun. Adhes. 18(6):133–43. doi: 10. 3109/ 15419061. 2011. 636465.

20. Shiozaki H, Oka H, Inoue M, Tamura A, Monden M. 1996. E-cadherin mediated adhesion system in cancer cells. Cancer. 77(8):1605–13. http://dx.doi.org/10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.0.CO;2-C; http://dx.doi.org/10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; http://dx.doi.org/10.1002/(SICI)1097-0142(19960415)77:8<1605::AID-CNCR28>3.0.CO;2-2

21. Van Aken E, De Wever O, Correia da Rocha AS, Mareel M. 2001. Defective E-cadherin/catenin complexes in human cancer. Virchows Arch. 439(6):725–51.

22. Yoshizawa Y, Yamada Y, Kanayama S, Shigetomi H, Kawa-guchi R, Yoshida S et al. 2011. Signaling pathway involved in cyclooxygenase-2 up-regulation by hepatocyte growth factor in endometrial cancer cells. Oncol. Rep. 26(4):957–64. http://dx.doi.org/10.3892/or.2011.1348.

23. Wagatsuma S, Konno R, Sato S, Yajima A. 1998. Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma. Cancer. 82(3):520–30. http://dx.doi.org/10.1002/(SICI)1097-0142(19980201)82:3<520::AID-CNCR14>3.0.CO;2-3

24. Edris F, Vilos GA, Al-Mubarak A, Ettler HC, Hollett-Caines J, Abu-Rafea B. 2007. Resectoscopic surgery may be an alternative to hysterectomy in high-risk women with atypical endometrial hyperplasia. J. Minim. Invasive Gynecol. 14(1):68–73. http://dx.doi.org/10.1016/j.jmig.2006.08.007; PMid:17218233

25. Somasunderam A, Thiviyanathan V, Tanaka T, Li X, Neerathilingam M, Lokesh GL et al. 2010. Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44. Biochemistry 49(42):9106–12. http://dx.doi.org/10.1021/bi1009503; PMid:20843027 PMCid:PMC2981344

26. Zhou J, Nagarkatti PS, Zhong Y, Creek K, Zhang J, Nagarkatti M. 2010. Unique SNP in CD44 intron1 and its role in breast cancer development. Anticancer Res. 30(4):1263–72.

27. Xu YY, Wu HJ, Ma HD, Xu LP, Huo Y, Yin LR. 2013. Micro-RNA-503 suppresses proliferation and cell-cycle progression of endometrioid endometrial cancer by negatively regulating cyclin D1. FEBS J. 280(16):3768–79.

28. Smetnik VP, Tumilovich LG. 2005. Non-immediate gynecology. Guide for physicians. 3rd ed. M, MIA:632.

29. Bray G. 1998. Lancet. 352:160–161.

30. Kogan EA, Askolskaya SI, Sagindykova RR, Fayzullina NM. 2014. Violation of protein expression of intercellular contacts and adhesion of endometrial hyperplasia, endometrial intraepithelial neoplasia, high-grade endometrioid adenocarcinoma. Obstetrics and Gynecology 11:68–73.

31. Shain M. 2003. Common sense in emergency abdominal surgery. M, GOETAR-MED:87.

32. Lasmar RB, Barrozo PR, de Oliveira MA, Coutinho ES, Dias R. 2006. Validation of hysteroscopic view in cases of endometrial hyperplasia and cancer in patients with abnormal uterine bleeding. J. Minim. Invasive Gynecol. 13(5):409–12. http://dx.doi.org/10.1016/j.jmig.2006.05.002; PMid:16962523

33. Garry R, Fountain J, Brown J, Manca A, Mason S, Sculpher M et al. 2004. EVALUATE hysterectomy trial: a multicentre randomized trial comparing abdominal, vaginal and laparoscopic methods of hysterectomy. Health Technol. Assess. 8(26):1–154.

34. Busund B, Erno LE, Grшnmark A, Istre O. 2003. Endometrial ablation with NovaSure GEA, a pilot study. Acta Obstet. Gynecol. Scand. 82(1):65–8.

35. Kurosawa H, Ito K, Nikura H, Takano T, Nagase S, Utsunomiya H et al. 2012. Hysteroscopic inspection and total curettage are insufficient for discriminationg endometrial cancer from atypical endometrial hyperplasia. Tohoku J. Exp. Med. 228(4):365–70.